Literature DB >> 17041899

Red cell glucose phosphate isomerase (GPI): a molecular study of three novel mutations associated with hereditary nonspherocytic hemolytic anemia.

Ada Repiso1, Baldomero Oliva, Joan-Lluis Vives-Corrons, Ernest Beutler, José Carreras, Fernando Climent.   

Abstract

Molecular characteristics of red blood cell (RBC) glucose phosphate isomerase (GPI) deficiency are described in two Spanish patients with chronic nonspherocytic hemolytic anemia. One patient, with residual GPI activity in RBCs of around 7% (GPI-Catalonia), is homozygous for the missense mutation c.1648A>G (p.Lys550Glu) in exon 18. The other patient, with residual activity in RBCs of around 20% (GPI-Barcelona), was found to be a compound heterozygote for two different missense mutations: c.341A>T (p.Asp113Val) in exon 4 and c.663T>G (p.Asn220Lys) in exon 7. Molecular modeling using the human crystal structure of GPI as a model was performed to determine how these mutations could affect enzyme structure and function. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17041899     DOI: 10.1002/humu.9466

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  2 in total

1.  Glucose Phosphate Isomerase Deficiency: High Prevalence of p.Arg347His Mutation in Indian Population Associated with Severe Hereditary Non-Spherocytic Hemolytic Anemia Coupled with Neurological Dysfunction.

Authors:  Prabhakar S Kedar; Rashmi Dongerdiye; Pooja Chilwirwar; Vinod Gupta; Ashish Chiddarwar; Rati Devendra; Prashant Warang; Harsha Prasada; Abhilasha Sampagar; Sunil Bhat; S Chandrakala; Manisha Madkaikar
Journal:  Indian J Pediatr       Date:  2019-04-27       Impact factor: 1.967

2.  Oxidation Resistance 1 Modulates Glycolytic Pathways in the Cerebellum via an Interaction with Glucose-6-Phosphate Isomerase.

Authors:  Mattéa J Finelli; Teresa Paramo; Elisabete Pires; Brent J Ryan; Richard Wade-Martins; Philip C Biggin; James McCullagh; Peter L Oliver
Journal:  Mol Neurobiol       Date:  2018-06-15       Impact factor: 5.590

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.